Effect of EGb 761 on the ratio of the isoforms of the protein precursor of beta amyloid platelets on patients with mild to moderate Alzheimer's disease. A phase II, randomised, double-blind trial, on parallel groups versus placebo

Trial Profile

Effect of EGb 761 on the ratio of the isoforms of the protein precursor of beta amyloid platelets on patients with mild to moderate Alzheimer's disease. A phase II, randomised, double-blind trial, on parallel groups versus placebo

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2013

At a glance

  • Drugs EGb 761 (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Jun 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 14 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top